医药生物行业报告（2025.09.22-2025.09.26）：关税实际影响小，下跌为创新药加仓良机

Investment Rating - The industry investment rating is "Outperform" [1] Core Insights - The report highlights that the recent tariff announcement by the U.S. government is expected to have a minimal impact on the pharmaceutical sector, suggesting that the current market downturn presents a good opportunity to increase positions in innovative drugs [4][13] - The report emphasizes the ongoing adjustments in the innovative drug sector, indicating that the recent price corrections are largely complete, and recommends maintaining or increasing exposure to high-quality stocks with growth potential [7][17] - The report discusses the positive outlook for the medical device sector due to new procurement policies aimed at preventing price wars, which could benefit companies previously affected by valuation pressures [8][23] Summary by Sections Industry Overview - The closing index for the pharmaceutical sector is 8770.86, with a weekly high of 9323.49 and a low of 6764.34 [1] Market Performance - For the week of September 22-26, 2025, the A-share pharmaceutical sector fell by 2.2%, underperforming the CSI 300 index by 3.27 percentage points and the ChiNext index by 4.16 percentage points [6][14][32] - The report ranks the pharmaceutical sector 26th among 31 first-level sub-industries in terms of weekly performance [14] Innovative Drugs - The innovative drug sector is experiencing a correction, with a recommendation to focus on high-quality stocks with growth potential, including companies like Innovent Biologics and Hengrui Medicine [7][17] Medical Devices - The National Healthcare Security Administration's new procurement policies are expected to positively impact the medical device sector, particularly benefiting companies like Mindray and Aohua [8][23] CDMO and CRO Sectors - The report expresses optimism about the CDMO sector's recovery, driven by increasing overseas demand and the upcoming interest rate cuts in the U.S. [18] - The CRO sector is also expected to see improved performance as domestic innovative drug demand stabilizes [18][19] Research Services - The report indicates a potential turnaround in the research services sector, with a focus on companies with strong competitive advantages [21] Biologics - The report notes that the blood products sector is currently facing downward pressure, while the vaccine sector is struggling due to declining birth rates and market saturation [22] Medical Services - The report highlights the potential for growth in the medical services sector, particularly for companies expanding their market share through acquisitions [26][27] Traditional Chinese Medicine - The report suggests that companies involved in innovative research and those benefiting from procurement policies are likely to see growth [28] Pharmaceutical Commerce - The report anticipates increased concentration in the retail pharmacy sector, with leading companies expected to gain market share [30][31]